共 50 条
Cell-Based Therapy for Therapeutic Lymphangiogenesis
被引:22
|作者:
Qi, Shuqun
[1
,2
]
Pan, Jian
[1
,2
]
机构:
[1] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Sichuan, Peoples R China
基金:
美国国家科学基金会;
关键词:
MESENCHYMAL STEM-CELLS;
HUMAN DENTAL-PULP;
MARROW STROMAL CELLS;
PROGENITOR ENDOTHELIAL-CELLS;
GROWTH-FACTOR RECEPTOR-3;
IN-VITRO;
POSTMASTECTOMY LYMPHEDEMA;
LYMPHATIC VASCULATURE;
PROX1;
EXPRESSION;
LOCAL INJECTION;
D O I:
10.1089/scd.2014.0390
中图分类号:
Q813 [细胞工程];
学科分类号:
摘要:
Lymphedema is a medically irreversible condition for which currently conservative and surgical therapies are either ineffective or impractical. The potential use of progenitor and stem cell-based therapies has offered a paradigm that may provide alternative treatment options for lymphatic disorders. Moreover, basic research, preclinical studies, as well as clinical trials have evaluated the therapeutic potential of various cell therapies in the field of lymphatic regeneration medicine. Among the available cell approaches, mesenchymal stem cells (MSCs) seem to be the most promising candidate mainly due to their abundant sources and easy availability as well as evitable ethical and immunological issues confronted with embryonic stem cells and induced pluripotent stem cells. In this context, the purpose of this review is to summarize various cell-based therapies for lymphedema, along with strengths and weaknesses of these therapies in the clinical application for lymphedema treatment. Particularly, we will highlight the use of MSCs for lymphatic regeneration medicine. In addition, the future perspectives of MSCs in the field of lymphatic regeneration will be discussed.
引用
收藏
页码:271 / 283
页数:13
相关论文